SUPN +23%Here we see a strong impulse and long correction during almost 2 years. Now it’s breakout and going higher.
0.03USD
1.32 MUSD
607.52 MUSD
52.39 M
About Supernus Pharmaceuticals, Inc.
Sector
CEO
Jack A. Khattar
Headquarters
Rockville
Website
Employees (FY)
652
Founded
2005
ISIN
US8684591089
FIGI
BBG000BP0HX7
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
SUPN going upWhat used to be a resistance now a support.
Plus an inverse head & shoulders.
Plus positive news: “Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.'"
Going long anticipating 30’s where MA200 is and then maybe higher.
With tight s
$SUPN Supernus Pharmaceuticals Bull flag This share reports earnings today. Downtrend broken and building what looks like a bull flag. Targets 29.40 and 33 if this bull flag breaks to the upside.
SUPN LongMonthly trend change on wave trend indicator. 4 hour chart looks strong. VIX oversold signal screaming oversold. What's not to like?
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SUPN is 29.00 USD — it has decreased by 1.46% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Supernus Pharmaceuticals, Inc. stocks are traded under the ticker SUPN.
Supernus Pharmaceuticals, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Supernus Pharmaceuticals, Inc. has a max estimate of 43.00 USD and a min estimate of 38.00 USD.
SUPN earnings for the last quarter are −0.29 USD whereas the estimation was 0.01 USD which accounts for −5.90 K% surprise. Estimated earnings for the next quarter are 0.55 USD. See more details about Supernus Pharmaceuticals, Inc. earnings.
Supernus Pharmaceuticals, Inc. revenue for the last quarter amounts to 153.88 M USD despite the estimated figure of 146.17 M USD. In the next quarter revenue is expected to reach 155.03 M USD.
Yes, you can track Supernus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
SUPN stock has fallen by 6.36% compared to the previous week, the month change is a 12.52% fall, over the last year Supernus Pharmaceuticals, Inc. has showed a 21.09% decrease.
Like other stocks, SUPN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Supernus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 652.00 employees. See our rating of the largest employees — is Supernus Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Supernus Pharmaceuticals, Inc. EBITDA is 98.25 M USD, and current EBITDA margin is 16.17%. See more stats in Supernus Pharmaceuticals, Inc. financial statements.